The Europe Ulcerative Colitis Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
One of the primary aspects regulating the total industry is the advent of biosimilars. Biosimilars should be less expensive than biologics, making them more affordable in developing countries. One of the factors driving the emergence of new biosimilars is the projected patent expiration of some medications. Moreover, the industry is expected to be driven by the increased engagement of important firms in product development connected to the field. Pfizer, for example, started a phase III clinical trial in June 2021 to evaluate tofacitinib's effectiveness, safety, and pharmacokinetics (PK) in juvenile patients with moderately to severely active Ulcerative Colitis.
In October 2028, the experiment is projected to be completed. Takeda Pharmaceutical Company Limited began a phase III research trial in Japan in June 2021 to evaluate the efficacy and safety of intravenous (IV) Vedolizumab in Japanese patients with moderate to severe Ulcerative Colitis. In September 2024, the experiment is projected to be completed. However, market growth is projected to be hampered by factors like high levels of unmet clinical need in ulcerative colitis (UC) and medication side effects over the projection period.
The European region is characterized by the government's supportive policies. In addition, economic growth and enhanced healthcare services are the major trends in the regional market. Clinical-stage businesses working on new IBD treatments would help the regional market to expand further. Sterna Biologicals, a clinical-stage firm based in Germany, is undertaking phase IIb clinical studies for the treatment of ulcerative colitis. Galapagos NV, a research-based business, is also undertaking phase 3 clinical studies for Filgotinib, a JAK inhibitor, to treat Crohn's disease and ulcerative colitis. In the next two to three years, the medicine is expected to be approved for IBD treatment.
Furthermore, the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) estimates that 3.4 million people in Europe will be living with IBD in 2020. IBD is affecting a growing number of individuals, thus boosting the demand for appropriate treatment alternatives. Hence, these aspects are anticipated to open new growth avenues for the players operating in the Ulcerative Colitis Market over the forecast years.
The Germany market dominated the Europe Ulcerative Colitis Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $594.8 million by 2028. The UK market is poised to grow at a CAGR of 4.4% during (2022 - 2028). Additionally, The France market would display a CAGR of 6% during (2022 - 2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Ulcerative Colitis Market Size will Hit $9 Billion by 2028, at a CAGR of 5.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
ByMolecule Type
- Small Molecules
- Biologics
By Disease Type
By Route of Administration
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Ulcerative Colitis Market, by Molecule Type
1.4.2 Europe Ulcerative Colitis Market, by Disease Type
1.4.3 Europe Ulcerative Colitis Market, by Route of Administration
1.4.4 Europe Ulcerative Colitis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Ulcerative Colitis Market
Chapter 4. Europe Ulcerative Colitis Market by Molecule Type
4.1 Europe Small Molecules Market by Country
4.2 Europe Biologics Market by Country
Chapter 5. Europe Ulcerative Colitis Market by Disease Type
5.1 Europe Mild Market by Country
5.2 Europe Moderate Market by Country
5.3 Europe Severe Market by Country
Chapter 6. Europe Ulcerative Colitis Market by Route of Administration
6.1 Europe Oral Market by Country
6.2 Europe Injectables Market by Country
Chapter 7. Europe Ulcerative Colitis Market by Country
7.1 Germany Ulcerative Colitis Market
7.1.1 Germany Ulcerative Colitis Market by Molecule Type
7.1.2 Germany Ulcerative Colitis Market by Disease Type
7.1.3 Germany Ulcerative Colitis Market by Route of Administration
7.2 UK Ulcerative Colitis Market
7.2.1 UK Ulcerative Colitis Market by Molecule Type
7.2.2 UK Ulcerative Colitis Market by Disease Type
7.2.3 UK Ulcerative Colitis Market by Route of Administration
7.3 France Ulcerative Colitis Market
7.3.1 France Ulcerative Colitis Market by Molecule Type
7.3.2 France Ulcerative Colitis Market by Disease Type
7.3.3 France Ulcerative Colitis Market by Route of Administration
7.4 Russia Ulcerative Colitis Market
7.4.1 Russia Ulcerative Colitis Market by Molecule Type
7.4.2 Russia Ulcerative Colitis Market by Disease Type
7.4.3 Russia Ulcerative Colitis Market by Route of Administration
7.5 Spain Ulcerative Colitis Market
7.5.1 Spain Ulcerative Colitis Market by Molecule Type
7.5.2 Spain Ulcerative Colitis Market by Disease Type
7.5.3 Spain Ulcerative Colitis Market by Route of Administration
7.6 Italy Ulcerative Colitis Market
7.6.1 Italy Ulcerative Colitis Market by Molecule Type
7.6.2 Italy Ulcerative Colitis Market by Disease Type
7.6.3 Italy Ulcerative Colitis Market by Route of Administration
7.7 Rest of Europe Ulcerative Colitis Market
7.7.1 Rest of Europe Ulcerative Colitis Market by Molecule Type
7.7.2 Rest of Europe Ulcerative Colitis Market by Disease Type
7.7.3 Rest of Europe Ulcerative Colitis Market by Route of Administration
Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Ajinomoto Co., Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental & Regional Analysis
8.2.4 Research & Development Expenses
8.3 AstraZeneca PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.4 GlaxoSmithKline PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.5 Johnson & Johnson
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental &Regional Analysis
8.5.4 Research & Development Expenses
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Pfizer, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Approvals and Trials:
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 InDex Pharmaceuticals Holding AB
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Recent strategies and developments:
8.9.3.1 Partnerships, Collaborations, and Agreements:
8.10. Eli Lilly And Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
TABLE 1 Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 2 Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 3 Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 4 Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 5 Europe Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Biologics Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Biologics Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 10 Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 11 Europe Mild Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Mild Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Moderate Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Moderate Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Severe Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Severe Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 18 Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 19 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Injectables Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Injectables Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 25 Germany Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 26 Germany Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 27 Germany Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 28 Germany Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 29 Germany Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 30 Germany Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 31 Germany Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 32 Germany Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 33 UK Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 34 UK Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 35 UK Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 36 UK Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 37 UK Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 UK Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 UK Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 40 UK Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 41 France Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 42 France Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 43 France Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 44 France Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 45 France Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 France Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 France Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 France Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 Russia Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 50 Russia Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 51 Russia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 52 Russia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 53 Russia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 Russia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 Russia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 56 Russia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 57 Spain Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 58 Spain Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 59 Spain Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 60 Spain Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 61 Spain Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 Spain Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 Spain Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 64 Spain Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 65 Italy Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 66 Italy Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 67 Italy Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 68 Italy Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 69 Italy Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 Italy Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 Italy Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 Italy Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 Rest of Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 74 Rest of Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 75 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 76 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 77 Rest of Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Rest of Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 80 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 81 Key Information – Abbott Laboratories
TABLE 82 Key information – Ajinomoto Co., Inc.
TABLE 83 KEY INFORMATION – ASTRAZENECA PLC
TABLE 84 Key Information – GlaxoSmithKline PLC
TABLE 85 Key information – Johnson & Johnson
TABLE 86 KEY INFORMATION - MERCK & CO., INC.
TABLE 87 Key Information – Pfizer, Inc.
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key Information – InDex Pharmaceuticals Holding AB
TABLE 90 Key Information – Eli Lilly And Company
List of Figures
FIG 1 Methodology for the research